CYP 3.85% 25.0¢ cynata therapeutics limited

Ann: Successful Completion of Planned DSMB Review of DFU Trial, page-15

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,138 Posts.
    lightbulb Created with Sketch. 1194
    I genuinely welcome your contrarian posts.

    When you saw the DSMB announcement and remembers the MEND announcement it was like you were speaking for me and reminding the group. I do think some here misinterpreted the DSMB annoucement relating to MEND as being a sort of endorsement of trial design when it was not.

    But DFU in my opinion will he harder to stuff up the trial design for than was MEND.

    Yet on the MEND side issue, sepsis, ARDs and CAR-T remain legitimate areas in which good trial designs might test potential therapies that would have merit.

    My concern with DFU is not trial design its how much shareholder value has been retained by Ross Macdonald in his capacity as the steward of shareholder value in commercial in confidence arrangements with TekCyte.

    With respect to milestones - that get mentioned here - milestones that are not anticipated before being reached are of a different sort than those that are laid out as KPIs ahead of time.

    I accept Dr Jolanta Airey's statement that this "is a key milestone, which enables continued enrollment as planned" but it sound's to me like Ross speak.

    And Ross's name still appears at the end of the announcement as authorising as CEO and Managing Director and that to me is still bad news for the shares that that is the case.

    When Silviu spoke of milestones in the other MSC company you are aware of he used "major milestones" as a sort of way to mitigate failure to completely deliver to expectations set - like that a BLA resubmission would be made by end of the quarter.

    In my opinion, CYPs near term share price gains are likely dependent on what MSB does, because CYP isn't hardly doing anything. Unfortunately I don't think MSB is on a positive trajectory either - MSB has just successfully gone dark on delivery dates without being pulled up on it and those delivery dates if they'd been met would have made Ross's planning of GvHD trials easier in my opinion because the FDA responding to MSB would have removed some of the fog.

    Yet fog remains.





 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.